EyePoint Pharmaceuticals, Inc. (EYPT)

NASDAQ: EYPT · IEX Real-Time Price · USD
11.12
+0.01 (0.09%)
At close: Aug 15, 2022 4:00 PM
10.57
-0.55 (-4.95%)
After-hours: Aug 15, 2022 7:09 PM EDT
0.09%
Market Cap 378.88M
Revenue (ttm) 41.46M
Net Income (ttm) -76.51M
Shares Out 34.07M
EPS (ttm) -2.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 122,025
Open 11.26
Previous Close 11.11
Day's Range 10.59 - 11.26
52-Week Range 7.00 - 21.50
Beta 1.26
Analysts Buy
Price Target 34.17 (+207.3%)
Earnings Date Aug 3, 2022

About EYPT

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treat... [Read more...]

Industry Pharmaceuticals
IPO Date Jan 27, 2005
Employees 122
Stock Exchange NASDAQ
Ticker Symbol EYPT
Full Company Profile

Financial Performance

In 2021, EYPT's revenue was $36.94 million, an increase of 7.27% compared to the previous year's $34.44 million. Losses were -$58.42 million, 28.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price forecast is 34.17, which is an increase of 207.28% from the latest price.

Price Target
$34.17
(207.28% upside)
Analyst Consensus: Buy
Stock Forecasts

News

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 8.77% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) –

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives ...

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintena...

-Topline data expected in the second half of 2023- WATERTOWN, Mass. , Aug. 1, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and com...

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives ...

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Finan...

- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng...

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evalu...

Data reinforces strong safety and efficacy for EYP-1901 as a potential six-month maintenance treatment for previously treated wet AMD No dose limiting toxicities, no ocular serious adverse events (SAEs)...

7 Wildly Oversold Nasdaq Stocks to Buy Now

For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. The post 7 Wildly Oversold Nasdaq Stocks to Buy Now appeared first on Investor...

Other symbols: ARBKCARCGCRIVNWOOFWW

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

- Guest speakers Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas -

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives ...

EyePoint Pharmaceuticals (EYPT) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

WATERTOWN, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives ...

EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YU...

WATERTOWN, Mass. and BEIJING, June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help i...

EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Tr...

WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the l...

EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives o...

Down 18.2% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...

EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) executed a license agreement with Betta Pharmaceuticals Co Ltd to develop and commercialize EYP-1901 in Mainland China, Hong Kong, Macau, and Taiwan.  This ag...

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD) at Angiogenesis, Exudation, and Degener...

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong ...

- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere -

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

WATERTOWN, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives...

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

WATERTOWN, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives...

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savings New structure replaces existing facility with a...